The choice to remove GLP-1 medications from Medi-Cal coverage carries consequences that go beyond line-item budgeting. For many patients, these drugs are not a lifestyle accessory but a medical intervention that assists with weight management, improved glycemic control and protection against organ complications. The decision risks leaving vulnerable groups—especially Black, Latino and low-income Californians—without access to a treatment option that can prevent serious, expensive sequelae of metabolic disease.
When preventative tools are taken away, clinicians and communities often see an increase in avoidable complications. Removing coverage does not erase obesity, diabetes or the rising burden of fatty liver disease; it shifts costs and suffering from a preventive framework to emergency and specialty care. For families already stretched thin, losing coverage can mean delayed care, worsening illness and higher long-term expenditures for the health system as a whole.
Why GLP-1 medications matter
GLP-1 drugs are backed by clinical evidence demonstrating benefits beyond weight loss. They assist with glycemic regulation, reduce inflammation and can slow the progression of metabolic liver disease. For individuals with insulin resistance or advanced metabolic dysfunction, access to these medicines can prevent irreversible outcomes such as liver failure, cardiovascular events and some cancers. Treating early is often far less costly and clinically more effective than waiting for complications to occur.
Clinical impact and disease connections
The intersection of obesity and diabetes often accelerates other conditions, notably metabolic liver disease. The term metabolic dysfunction-associated steatotic liver disease (MASLD) describes a spectrum that may advance silently to cirrhosis or liver cancer when left unmanaged. By helping to reduce excess weight and improve blood sugar, GLP-1 therapies contribute to a multi-pronged prevention strategy that can ease pressure on emergency departments and reduce the need for costly interventions down the line.
Equity implications of changing Medi-Cal coverage
Health coverage decisions have uneven effects when underlying social determinants of health are unequal. In San Diego County and across California, data show higher rates of diabetes-related hospital visits and mortality among Black residents and other underserved populations. Removing GLP-1 access from Medi-Cal risks creating or deepening a two-tier system: those with private insurance or means retain preventive options while Medi-Cal beneficiaries face a reactive care pathway dominated by advanced disease management.
Economic and human costs
Policy-makers sometimes focus narrowly on immediate savings. Yet the economic picture changes when downstream costs are included. Complications such as dialysis for kidney failure, limb amputations, heart attacks, strokes and liver cancer require intensive, expensive care and often long-term disability supports. Beyond dollars, there are social and emotional costs when family members lose years of life or the ability to work. Preventive access through Medi-Cal aligns fiscal prudence with public health when long-term outcomes are accounted for.
What a prevention-first approach looks like
A health system prioritizing prevention would maintain coverage for evidence-based treatments, combine medication access with nutrition and lifestyle support, and ensure culturally competent care tailored to community needs. Restoring or preserving GLP-1 coverage in Medi-Cal would be one element of a strategy focused on health equity, chronic disease management and cost avoidance. Policymakers should weigh the full trajectory of illness when assessing budget choices, not only the initial price tag of therapies.
California faces a choice: preserve short-term savings by narrowing access, or invest in interventions that keep people healthier and communities more resilient. For Black, Latino and low-income residents who already experience disproportionate chronic disease burdens, access to GLP-1 medications through Medi-Cal is not a luxury — it is a component of fair, effective public health policy.
About the author: Neshea V. Harrison, board president of the Liver Coalition of San Diego, advocates for policies that reduce liver disease through prevention and equitable access to care.
